Plate Nº 93 · recorded November 17, 2026
Health & Medicine ResearchReported finding
Regret Is Rare Among Transgender Youth Who Started Hormone Therapy
Only 2.7% of 372 former U.S. gender-clinic patients regretted starting hormone therapy as youth, the largest decisional-regret study finds — though 17.3% had stopped treatment.
By Priya Raman4 min read872 words
In brief
- 2.7% of 372 respondents regretted starting hormone therapy; average regret scored 4.3 of 100 versus 16.5 for other medical decisions.
- 96.8% still affirmed starting treatment was right an average of 4.9 years later.
- 17.3% had stopped hormones, yet 83% of them still called starting treatment the right decision.
- Study led by Laura Kuper, published in JAMA Pediatrics, surveyed 376 of 698 invited former patients at one U.S. clinic.
- Nonbinary identity carried almost nine times higher odds of not currently receiving hormone therapy.

Only 2.7% of former patients who began hormone therapy as teenagers at a U.S. gender clinic said they regretted the decision, according to the largest study to date on the question, published in JAMA Pediatrics. Nearly five years after starting treatment on average, 96.8% of respondents still agreed that beginning hormone therapy had been the right choice — and even among those who had stopped taking hormones, more than four out of five stood by the initial decision.
The findings arrive amid ongoing policy debates in the United States over adolescent gender-affirming care, where concerns about regret have fueled restrictions in many states. Gender-affirming hormone therapy involves taking prescribed estrogen or testosterone to develop physical traits aligned with a person's gender identity rather than their sex assigned at birth. Estrogen promotes breast growth and softer skin; testosterone deepens the voice and stimulates facial and body hair, with some effects becoming permanent over time. An estimated 3.3% of U.S. teenagers identify as transgender or gender-diverse, though fewer than 0.1% of adolescents receive hormone therapy.
What did the study measure?
Laura Kuper of the University of Texas Southwestern Medical Center led the research, joined by co-authors Megan Ungerman, Bree Horrocks, Diane Chen, and Ximena Lopez. Between October 2023 and October 2025, the team invited 698 former patients of a multidisciplinary pediatric gender program who had previously agreed to longitudinal research to complete annual online surveys, explicitly encouraging participation from people who had stopped hormones or left the clinic. Of 376 participants who started estrogen or testosterone as youth, 372 completed the Decision Regret Scale, a five-item questionnaire scored 0 to 100 that asks whether treatment was the right decision, whether the person regrets it, and whether it did them harm.
The sample skewed toward patients assigned female at birth: roughly 70% initiated testosterone and about 30% initiated estrogen. Nearly 92% began hormones at age 17 or younger, at an average starting age of 16, and participants were 14 to 28 years old when surveyed. Follow-up periods ranged from just over a month to nearly 11 years.
What were the results?
- Average regret scored 4.3 out of 100, with a median of zero — well below the 16.5 average reported for other medical decisions using the same scale.
- 96.8% (360 people) agreed or strongly agreed starting treatment was right; 1.9% (7 people, all also reporting regret) said it did them a lot of harm.
- In total, 13 people ever indicated regret or harm across survey waves; 12 had stopped hormones and seven now identified exclusively with their birth-assigned sex.
Most participants — 82.7%, or 311 individuals — were still taking hormones. Among the 65 who had stopped, about 14% reported regret, yet 83% still affirmed the decision to start. Nine respondents explained their regret in writing: seven cited inadequate preparation due to age, maturity, mental health difficulties, or insufficient parental or therapeutic support; six described unwanted physical effects such as body hair, voice deepening, or breast growth; and four cited adverse effects including mood shifts, vaginal atrophy (a thinning and drying of vaginal tissue), or fertility concerns.
Neither regret nor discontinuation was significantly linked to starting age, age of first identifying as transgender, or childhood-onset gender distress — distress over a mismatch between gender identity and assigned sex. The authors note the small number of regret cases limited statistical power to detect such links.
How reliable are the findings?
Aleksandra M. Rogowska, director of the Institute of Psychology at the University of Opole in Poland, who was not involved in the study, told PsyPost: "Among the respondents, about five years after starting hormone therapy on average, satisfaction with the decision was very high and regret was rare (2.7%)." The findings "largely confirm earlier clinic-based studies reporting regret rates of 0–4%."
Still, she flagged key caveats. Nearly 300 invited patients did not respond. "'2.7% regret' is not a population rate. It describes those who chose to respond," she said, adding that people who stopped or regret treatment may be less likely to answer a survey from the clinic that treated them, which would push the estimate downward. She described her confidence as "moderate for the descriptive findings and low for any broader generalization," cautioned that a mean follow-up of 4.9 years may miss regret emerging later, and warned against overreading the null findings: "With only 13 participants reporting regret, the study had very little power to detect such effects."
The single-clinic design also limits generalization: all participants received multidisciplinary care with parental consent, and more than 93% were White. The survey measured regret about the initial decision, not satisfaction with specific physical effects, and never asked the broader group who stopped why they discontinued.
The authors conclude the results support existing standards of care and do not justify categorical bans. Rogowska urged caution: "The authors' policy conclusions go further than a single-site observational study can support, in either direction." She called for multi-site prospective cohorts, independent of treating clinics, with follow-up of 10 years or more — noting that nonbinary identity carried almost nine times higher odds of not currently receiving therapy.
via psypost.org (Source)
More from Priya Raman
Show full bio
Senior reporter covering people, launches and day-to-day practice in general science news at SciBeat.
476 articles
Nearby plates
- 97% in youth hormone survey call treatment the right decision
- Drug That Destroys Testosterone Receptors Slashes Prostate Cancer Marker
- Steroid Users Face Triple the Risk of Long-Term Erectile Dysfunction
- Low Testosterone Linked to 18% Higher Cancer Death Risk in 26,000-Man Study
- Neuroscience Reports of Sex Differences Often Rest on Weak Evidence